Lupin shares in focus after signing license and supply agreement for Semaglutide in 23 countries

Lupin Ltd., the drug manufacturer, announced on Wednesday, January 21, that its subsidiary, Lupin Atlantis Holdings SA, has signed a licensing and supply agreement through its subsidiary Lupin Atlantis Holdings SA, with Galenicum Health, S.L.U.

The agreement is for finished formulations of injectable Semaglutide, a GLP-1 receptor agonist.

Based on the agreement, Galenicum will oversee the development, manufacturing, and supply of Semaglutide, while Lupin will be in charge of regulatory submissions, approvals, commercialization and distribution of Semaglutide across 23 countries.

Canada, Europe, Southeast Asia, and Latin America are among the 23 countries in this list. "Lupin is well-positioned to expand its leadership in diabetes care and obesity beyond India with this Semaglutide partnership," Lupin said in its exchange filing.

The Galenicum partnership will strengthen Lupin's Semaglutide portfolio, as it stands out as a critical therapy amidst escalating issue of diabetes globally.

"With our extensive commercial presence across Canada, Europe, Southeast Asia, and Latin America we are positioned to scale access at the right moment – further reinforcing our commitment to delivering high-quality, cost-effective medicines and expanding access to Semaglutide for patients in these regions," said Fabrice Egros, President of Corporate Development at Lupin said.

Semaglutide is a glucagon-like Peptide-1, helping in blood sugar regulation.

Shares of Lupin had ended 0.6% lower on Tuesday at ₹2,165. The stock has risen only 3% over the last 12 months.